🇺🇸 Integrase Inhibitor in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Amylase Increased — 1 report (10%)
- Diarrhoea — 1 report (10%)
- Headache — 1 report (10%)
- Insomnia — 1 report (10%)
- Iridocyclitis — 1 report (10%)
- Kaposi'S Sarcoma — 1 report (10%)
- Malabsorption — 1 report (10%)
- Mesenteric Vein Thrombosis — 1 report (10%)
- Mycobacterium Avium Complex Infection — 1 report (10%)
- Nausea — 1 report (10%)
Other Infectious Disease approved in United States
Frequently asked questions
Is Integrase Inhibitor approved in United States?
Integrase Inhibitor does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Integrase Inhibitor in United States?
McGill University Health Centre/Research Institute of the McGill University Health Centre is the originator. The local marketing authorisation holder may differ — check the official source linked above.